Regulation and Transfer of a Murine Model of Thyrotropin Receptor Antibody Mediated Graves’ Disease

Abstract In order to replicate a recently described murine model of Graves’ disease, we immunized AKR/N (H-2k) mice ip, every 2 weeks, with either a clone of fibroblasts expressing both the human TSH receptor (hTSHR) and murine major histocompatibility complex (MHC) class II molecules or with fibrob...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Endocrinology (Philadelphia) 1999-03, Vol.140 (3), p.1392-1398
Hauptverfasser: Kita, M., Ahmad, L., Marians, R. C., Vlase, H., Unger, P., Graves, P. N., Davies, T. F.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1398
container_issue 3
container_start_page 1392
container_title Endocrinology (Philadelphia)
container_volume 140
creator Kita, M.
Ahmad, L.
Marians, R. C.
Vlase, H.
Unger, P.
Graves, P. N.
Davies, T. F.
description Abstract In order to replicate a recently described murine model of Graves’ disease, we immunized AKR/N (H-2k) mice ip, every 2 weeks, with either a clone of fibroblasts expressing both the human TSH receptor (hTSHR) and murine major histocompatibility complex (MHC) class II molecules or with fibroblasts expressing the MHC class II molecules alone. Mice were bled, and their thyroid hormone levels measured, at 6, 12, and up to 18 weeks after the first immunization. Between 11–12 weeks after immunization, a significant number of mice began to die spontaneously and were found to have developed large goiters. Thirty to 40% of mice immunized with hTSHR transfected fibroblasts showed markedly increased serum T3 and T4 hormone levels by 12 weeks compared with controls, with the highest thyroid hormone levels being T3: 420 ng/dl (normal < 70) and T4: 16.5 μg/dl (normal < 5). The murine serum demonstrated the presence of antibodies to the TSHR, as evidenced by inhibition of labeled TSH binding to the hTSHR, and these sera had in vitro thyroid stimulating activity. Many of the hyperthyroid mouse exhibited weight loss and hyperactivity and, on examination, their thyroids had the histological features of thyroid hyperactivity including thyroid enlargement, thyroid cell hypertrophy, and colloid droplet formation - all consistent with Graves’ disease. In contrast, a small number of mice (< 5%) developed hypothyroidism with low serum T4 levels and markedly increased TSH concentrations and evidence of thyroid hypoplasia. Both hyperthyroidism and hypothyroidism were successfully transferred to naive mice using ip cells of immunized mice. Surprisingly, hypothyroidism occurred in many recipient mice even after transfer from hyperthyroid donors. These results confirmed that immunization with naturally expressed hTSHR in mammalian cells was able to induce functional TSHR autoantibodies that either stimulated or blocked the mouse thyroid gland and induced hyperthyroidism or thyroid failure. Furthermore, both blocking and stimulating antibodies coexisted in the same mice as evidenced so clearly by the transfer of hypothyroidism from hyperthyroid mice. The addition of a Th2 adjuvant (pertussis toxin) caused approximately 50% of the animals to become hyperthyroid beginning early at 9 weeks, whereas a Th1 adjuvant (CFA) delayed the disease onset such that only 10% were hyperthyroid by 12 weeks. As with human autoimmune thyroid disease, the T cell control of this murine model may be
doi_str_mv 10.1210/endo.140.3.6599
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_3130527054</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1210/endo.140.3.6599</oup_id><sourcerecordid>3130527054</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3249-d596337cdf0f86faa30dece588f37aa652a8743fdd5ab69982143196e34f2903</originalsourceid><addsrcrecordid>eNqFkMtKAzEUhoMoWKtrtwF3wkxznUyWxUsVWoQy-5BOTnRKnYzJjNCdr-Hr-SROqXtXh3P4_vPDh9A1JTlllMygdSGnguQ8L6TWJ2hCtZCZooqcogkhlGeKMXWOLlLajqsQgk8QrOF12Nm-CS22rcNVtG3yEHHw2OLVEJsW8Co42B0u1ds-hj6GrmnxGmro-hDxvO2bTXB7vALX2B4cXkT7Cenn6xvfNwlsgkt05u0uwdXfnKLq8aG6e8qWL4vnu_kyqzkTOnNSF5yr2nniy8Jby4kbW2RZeq6sLSSzpRLcOyftptC6ZFRwqgvgwjNN-BTdHN92MXwMkHqzDUNsx0bDKSeSKSLFSM2OVB1DShG86WLzbuPeUGIOKs1BpRlVGm4OKsfE7TERhu5f-BeXS3X4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3130527054</pqid></control><display><type>article</type><title>Regulation and Transfer of a Murine Model of Thyrotropin Receptor Antibody Mediated Graves’ Disease</title><source>Oxford Journals - Connect here FIRST to enable access</source><source>EZB Electronic Journals Library</source><creator>Kita, M. ; Ahmad, L. ; Marians, R. C. ; Vlase, H. ; Unger, P. ; Graves, P. N. ; Davies, T. F.</creator><creatorcontrib>Kita, M. ; Ahmad, L. ; Marians, R. C. ; Vlase, H. ; Unger, P. ; Graves, P. N. ; Davies, T. F.</creatorcontrib><description>Abstract In order to replicate a recently described murine model of Graves’ disease, we immunized AKR/N (H-2k) mice ip, every 2 weeks, with either a clone of fibroblasts expressing both the human TSH receptor (hTSHR) and murine major histocompatibility complex (MHC) class II molecules or with fibroblasts expressing the MHC class II molecules alone. Mice were bled, and their thyroid hormone levels measured, at 6, 12, and up to 18 weeks after the first immunization. Between 11–12 weeks after immunization, a significant number of mice began to die spontaneously and were found to have developed large goiters. Thirty to 40% of mice immunized with hTSHR transfected fibroblasts showed markedly increased serum T3 and T4 hormone levels by 12 weeks compared with controls, with the highest thyroid hormone levels being T3: 420 ng/dl (normal &lt; 70) and T4: 16.5 μg/dl (normal &lt; 5). The murine serum demonstrated the presence of antibodies to the TSHR, as evidenced by inhibition of labeled TSH binding to the hTSHR, and these sera had in vitro thyroid stimulating activity. Many of the hyperthyroid mouse exhibited weight loss and hyperactivity and, on examination, their thyroids had the histological features of thyroid hyperactivity including thyroid enlargement, thyroid cell hypertrophy, and colloid droplet formation - all consistent with Graves’ disease. In contrast, a small number of mice (&lt; 5%) developed hypothyroidism with low serum T4 levels and markedly increased TSH concentrations and evidence of thyroid hypoplasia. Both hyperthyroidism and hypothyroidism were successfully transferred to naive mice using ip cells of immunized mice. Surprisingly, hypothyroidism occurred in many recipient mice even after transfer from hyperthyroid donors. These results confirmed that immunization with naturally expressed hTSHR in mammalian cells was able to induce functional TSHR autoantibodies that either stimulated or blocked the mouse thyroid gland and induced hyperthyroidism or thyroid failure. Furthermore, both blocking and stimulating antibodies coexisted in the same mice as evidenced so clearly by the transfer of hypothyroidism from hyperthyroid mice. The addition of a Th2 adjuvant (pertussis toxin) caused approximately 50% of the animals to become hyperthyroid beginning early at 9 weeks, whereas a Th1 adjuvant (CFA) delayed the disease onset such that only 10% were hyperthyroid by 12 weeks. As with human autoimmune thyroid disease, the T cell control of this murine model may be critical and requires more extensive investigation.</description><identifier>ISSN: 0013-7227</identifier><identifier>EISSN: 1945-7170</identifier><identifier>DOI: 10.1210/endo.140.3.6599</identifier><language>eng</language><publisher>Washington: Oxford University Press</publisher><subject>Animal models ; Antibodies ; Autoantibodies ; Disease control ; Fibroblasts ; Graves disease ; Hyperthyroidism ; Hypertrophy ; Hypoplasia ; Hypothyroidism ; Immunization ; Lymphocytes ; Lymphocytes T ; Major histocompatibility complex ; Mammalian cells ; Pertussis ; Pertussis toxin ; Receptors ; Thyroid ; Thyroid diseases ; Thyroid gland ; Thyroid-stimulating hormone ; Thyroid-stimulating hormone receptors ; Thyroxine ; Toxins ; Triiodothyronine ; Weight loss</subject><ispartof>Endocrinology (Philadelphia), 1999-03, Vol.140 (3), p.1392-1398</ispartof><rights>Copyright © 1999 by The Endocrine Society 1999</rights><rights>Copyright © 1999 by The Endocrine Society</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3249-d596337cdf0f86faa30dece588f37aa652a8743fdd5ab69982143196e34f2903</citedby><cites>FETCH-LOGICAL-c3249-d596337cdf0f86faa30dece588f37aa652a8743fdd5ab69982143196e34f2903</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Kita, M.</creatorcontrib><creatorcontrib>Ahmad, L.</creatorcontrib><creatorcontrib>Marians, R. C.</creatorcontrib><creatorcontrib>Vlase, H.</creatorcontrib><creatorcontrib>Unger, P.</creatorcontrib><creatorcontrib>Graves, P. N.</creatorcontrib><creatorcontrib>Davies, T. F.</creatorcontrib><title>Regulation and Transfer of a Murine Model of Thyrotropin Receptor Antibody Mediated Graves’ Disease</title><title>Endocrinology (Philadelphia)</title><description>Abstract In order to replicate a recently described murine model of Graves’ disease, we immunized AKR/N (H-2k) mice ip, every 2 weeks, with either a clone of fibroblasts expressing both the human TSH receptor (hTSHR) and murine major histocompatibility complex (MHC) class II molecules or with fibroblasts expressing the MHC class II molecules alone. Mice were bled, and their thyroid hormone levels measured, at 6, 12, and up to 18 weeks after the first immunization. Between 11–12 weeks after immunization, a significant number of mice began to die spontaneously and were found to have developed large goiters. Thirty to 40% of mice immunized with hTSHR transfected fibroblasts showed markedly increased serum T3 and T4 hormone levels by 12 weeks compared with controls, with the highest thyroid hormone levels being T3: 420 ng/dl (normal &lt; 70) and T4: 16.5 μg/dl (normal &lt; 5). The murine serum demonstrated the presence of antibodies to the TSHR, as evidenced by inhibition of labeled TSH binding to the hTSHR, and these sera had in vitro thyroid stimulating activity. Many of the hyperthyroid mouse exhibited weight loss and hyperactivity and, on examination, their thyroids had the histological features of thyroid hyperactivity including thyroid enlargement, thyroid cell hypertrophy, and colloid droplet formation - all consistent with Graves’ disease. In contrast, a small number of mice (&lt; 5%) developed hypothyroidism with low serum T4 levels and markedly increased TSH concentrations and evidence of thyroid hypoplasia. Both hyperthyroidism and hypothyroidism were successfully transferred to naive mice using ip cells of immunized mice. Surprisingly, hypothyroidism occurred in many recipient mice even after transfer from hyperthyroid donors. These results confirmed that immunization with naturally expressed hTSHR in mammalian cells was able to induce functional TSHR autoantibodies that either stimulated or blocked the mouse thyroid gland and induced hyperthyroidism or thyroid failure. Furthermore, both blocking and stimulating antibodies coexisted in the same mice as evidenced so clearly by the transfer of hypothyroidism from hyperthyroid mice. The addition of a Th2 adjuvant (pertussis toxin) caused approximately 50% of the animals to become hyperthyroid beginning early at 9 weeks, whereas a Th1 adjuvant (CFA) delayed the disease onset such that only 10% were hyperthyroid by 12 weeks. As with human autoimmune thyroid disease, the T cell control of this murine model may be critical and requires more extensive investigation.</description><subject>Animal models</subject><subject>Antibodies</subject><subject>Autoantibodies</subject><subject>Disease control</subject><subject>Fibroblasts</subject><subject>Graves disease</subject><subject>Hyperthyroidism</subject><subject>Hypertrophy</subject><subject>Hypoplasia</subject><subject>Hypothyroidism</subject><subject>Immunization</subject><subject>Lymphocytes</subject><subject>Lymphocytes T</subject><subject>Major histocompatibility complex</subject><subject>Mammalian cells</subject><subject>Pertussis</subject><subject>Pertussis toxin</subject><subject>Receptors</subject><subject>Thyroid</subject><subject>Thyroid diseases</subject><subject>Thyroid gland</subject><subject>Thyroid-stimulating hormone</subject><subject>Thyroid-stimulating hormone receptors</subject><subject>Thyroxine</subject><subject>Toxins</subject><subject>Triiodothyronine</subject><subject>Weight loss</subject><issn>0013-7227</issn><issn>1945-7170</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><recordid>eNqFkMtKAzEUhoMoWKtrtwF3wkxznUyWxUsVWoQy-5BOTnRKnYzJjNCdr-Hr-SROqXtXh3P4_vPDh9A1JTlllMygdSGnguQ8L6TWJ2hCtZCZooqcogkhlGeKMXWOLlLajqsQgk8QrOF12Nm-CS22rcNVtG3yEHHw2OLVEJsW8Co42B0u1ds-hj6GrmnxGmro-hDxvO2bTXB7vALX2B4cXkT7Cenn6xvfNwlsgkt05u0uwdXfnKLq8aG6e8qWL4vnu_kyqzkTOnNSF5yr2nniy8Jby4kbW2RZeq6sLSSzpRLcOyftptC6ZFRwqgvgwjNN-BTdHN92MXwMkHqzDUNsx0bDKSeSKSLFSM2OVB1DShG86WLzbuPeUGIOKs1BpRlVGm4OKsfE7TERhu5f-BeXS3X4</recordid><startdate>19990301</startdate><enddate>19990301</enddate><creator>Kita, M.</creator><creator>Ahmad, L.</creator><creator>Marians, R. C.</creator><creator>Vlase, H.</creator><creator>Unger, P.</creator><creator>Graves, P. N.</creator><creator>Davies, T. F.</creator><general>Oxford University Press</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7QG</scope><scope>7QP</scope><scope>7QR</scope><scope>7T5</scope><scope>7TM</scope><scope>7TO</scope><scope>7U7</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>P64</scope></search><sort><creationdate>19990301</creationdate><title>Regulation and Transfer of a Murine Model of Thyrotropin Receptor Antibody Mediated Graves’ Disease</title><author>Kita, M. ; Ahmad, L. ; Marians, R. C. ; Vlase, H. ; Unger, P. ; Graves, P. N. ; Davies, T. F.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3249-d596337cdf0f86faa30dece588f37aa652a8743fdd5ab69982143196e34f2903</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Animal models</topic><topic>Antibodies</topic><topic>Autoantibodies</topic><topic>Disease control</topic><topic>Fibroblasts</topic><topic>Graves disease</topic><topic>Hyperthyroidism</topic><topic>Hypertrophy</topic><topic>Hypoplasia</topic><topic>Hypothyroidism</topic><topic>Immunization</topic><topic>Lymphocytes</topic><topic>Lymphocytes T</topic><topic>Major histocompatibility complex</topic><topic>Mammalian cells</topic><topic>Pertussis</topic><topic>Pertussis toxin</topic><topic>Receptors</topic><topic>Thyroid</topic><topic>Thyroid diseases</topic><topic>Thyroid gland</topic><topic>Thyroid-stimulating hormone</topic><topic>Thyroid-stimulating hormone receptors</topic><topic>Thyroxine</topic><topic>Toxins</topic><topic>Triiodothyronine</topic><topic>Weight loss</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kita, M.</creatorcontrib><creatorcontrib>Ahmad, L.</creatorcontrib><creatorcontrib>Marians, R. C.</creatorcontrib><creatorcontrib>Vlase, H.</creatorcontrib><creatorcontrib>Unger, P.</creatorcontrib><creatorcontrib>Graves, P. N.</creatorcontrib><creatorcontrib>Davies, T. F.</creatorcontrib><collection>CrossRef</collection><collection>Animal Behavior Abstracts</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>Endocrinology (Philadelphia)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kita, M.</au><au>Ahmad, L.</au><au>Marians, R. C.</au><au>Vlase, H.</au><au>Unger, P.</au><au>Graves, P. N.</au><au>Davies, T. F.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Regulation and Transfer of a Murine Model of Thyrotropin Receptor Antibody Mediated Graves’ Disease</atitle><jtitle>Endocrinology (Philadelphia)</jtitle><date>1999-03-01</date><risdate>1999</risdate><volume>140</volume><issue>3</issue><spage>1392</spage><epage>1398</epage><pages>1392-1398</pages><issn>0013-7227</issn><eissn>1945-7170</eissn><abstract>Abstract In order to replicate a recently described murine model of Graves’ disease, we immunized AKR/N (H-2k) mice ip, every 2 weeks, with either a clone of fibroblasts expressing both the human TSH receptor (hTSHR) and murine major histocompatibility complex (MHC) class II molecules or with fibroblasts expressing the MHC class II molecules alone. Mice were bled, and their thyroid hormone levels measured, at 6, 12, and up to 18 weeks after the first immunization. Between 11–12 weeks after immunization, a significant number of mice began to die spontaneously and were found to have developed large goiters. Thirty to 40% of mice immunized with hTSHR transfected fibroblasts showed markedly increased serum T3 and T4 hormone levels by 12 weeks compared with controls, with the highest thyroid hormone levels being T3: 420 ng/dl (normal &lt; 70) and T4: 16.5 μg/dl (normal &lt; 5). The murine serum demonstrated the presence of antibodies to the TSHR, as evidenced by inhibition of labeled TSH binding to the hTSHR, and these sera had in vitro thyroid stimulating activity. Many of the hyperthyroid mouse exhibited weight loss and hyperactivity and, on examination, their thyroids had the histological features of thyroid hyperactivity including thyroid enlargement, thyroid cell hypertrophy, and colloid droplet formation - all consistent with Graves’ disease. In contrast, a small number of mice (&lt; 5%) developed hypothyroidism with low serum T4 levels and markedly increased TSH concentrations and evidence of thyroid hypoplasia. Both hyperthyroidism and hypothyroidism were successfully transferred to naive mice using ip cells of immunized mice. Surprisingly, hypothyroidism occurred in many recipient mice even after transfer from hyperthyroid donors. These results confirmed that immunization with naturally expressed hTSHR in mammalian cells was able to induce functional TSHR autoantibodies that either stimulated or blocked the mouse thyroid gland and induced hyperthyroidism or thyroid failure. Furthermore, both blocking and stimulating antibodies coexisted in the same mice as evidenced so clearly by the transfer of hypothyroidism from hyperthyroid mice. The addition of a Th2 adjuvant (pertussis toxin) caused approximately 50% of the animals to become hyperthyroid beginning early at 9 weeks, whereas a Th1 adjuvant (CFA) delayed the disease onset such that only 10% were hyperthyroid by 12 weeks. As with human autoimmune thyroid disease, the T cell control of this murine model may be critical and requires more extensive investigation.</abstract><cop>Washington</cop><pub>Oxford University Press</pub><doi>10.1210/endo.140.3.6599</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0013-7227
ispartof Endocrinology (Philadelphia), 1999-03, Vol.140 (3), p.1392-1398
issn 0013-7227
1945-7170
language eng
recordid cdi_proquest_journals_3130527054
source Oxford Journals - Connect here FIRST to enable access; EZB Electronic Journals Library
subjects Animal models
Antibodies
Autoantibodies
Disease control
Fibroblasts
Graves disease
Hyperthyroidism
Hypertrophy
Hypoplasia
Hypothyroidism
Immunization
Lymphocytes
Lymphocytes T
Major histocompatibility complex
Mammalian cells
Pertussis
Pertussis toxin
Receptors
Thyroid
Thyroid diseases
Thyroid gland
Thyroid-stimulating hormone
Thyroid-stimulating hormone receptors
Thyroxine
Toxins
Triiodothyronine
Weight loss
title Regulation and Transfer of a Murine Model of Thyrotropin Receptor Antibody Mediated Graves’ Disease
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T15%3A11%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Regulation%20and%20Transfer%20of%20a%20Murine%20Model%20of%20Thyrotropin%20Receptor%20Antibody%20Mediated%20Graves%E2%80%99%20Disease&rft.jtitle=Endocrinology%20(Philadelphia)&rft.au=Kita,%20M.&rft.date=1999-03-01&rft.volume=140&rft.issue=3&rft.spage=1392&rft.epage=1398&rft.pages=1392-1398&rft.issn=0013-7227&rft.eissn=1945-7170&rft_id=info:doi/10.1210/endo.140.3.6599&rft_dat=%3Cproquest_cross%3E3130527054%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3130527054&rft_id=info:pmid/&rft_oup_id=10.1210/endo.140.3.6599&rfr_iscdi=true